Deal Struck to Distribute Ruconest in Middle East, North Africa

Deal Struck to Distribute Ruconest in Middle East, North Africa

300266

Deal Struck to Distribute Ruconest in Middle East, North Africa

Pharming Group has signed an exclusive license agreement with NewBridge Pharmaceuticals to distribute and commercialize Ruconest (conestat alfa), a treatment for acute attacks of hereditary angioedema (HAE), in the Middle East and North Africa. Under the agreement terms, NewBridge in collaboration with Pharming, will provide access for Ruconest, and NewBridge will be responsible for managing named patient supplies and marketing the therapy in the region. “Pharming is committed to supporting patients with HAE, along with…

You must be logged in to read/download the full post.